Cancer Drugs Fund requires further reform
Reliance on “real world” observational data undermines evidence base for clinical practice.
Hlavní autoři: | Grieve, R, Abrams, K, Claxton, K, Goldacre, B, James, N, Nicholl, J, Parmar, M, Parker, C, Sekhon, J, Smeeth, L, Spiegelhalter, D, Sculpher, M |
---|---|
Médium: | Journal article |
Jazyk: | English |
Vydáno: |
BMJ Publishing Group
2016
|
Podobné jednotky
-
Huang Shu Yin funded for further study
Autor: Kwong Wah, Yit Poh
Vydáno: (2017) -
Huang Shu Yin Funded For Further Study
Autor: Kwong Wah, Yit Poh
Vydáno: (2017) -
MRE in NAFLD: promising but further validation is required
Autor: Ryan, J, a další
Vydáno: (2018) -
Will the reformed Cancer Drugs Fund address the most common types of uncertainty? An analysis of NICE cancer drug appraisals
Autor: Morrell, L, a další
Vydáno: (2018) -
Bladder cancer: issues requiring further research
Autor: I. A. Rozhkov, a další
Vydáno: (2024-09-01)